Is dose adjustment of polymyxin B required in patients with renal disease?

No Dose Adjustment of Polymyxin B is Required in Renal Disease

Polymyxin B does NOT require dose adjustment based on renal function, including in patients with renal insufficiency or those on renal replacement therapy. This is a critical distinction from colistin, which does require renal dose adjustment.

Key Pharmacokinetic Principle

The plasma concentration of polymyxin B is not influenced by renal function 1. Unlike colistin (which is administered as the inactive prodrug colistimethate and requires renal dose adjustment), polymyxin B is administered as the active drug and is dosed based on body weight 1.

Recommended Dosing Strategy

Standard dosing for all patients regardless of renal function:

• Loading dose: 2-2.5 mg/kg (should be given to ALL patients, including those with renal dysfunction) 1
• Maintenance dose: 1.5-3 mg/kg/day divided in 2 doses 1

The FDA label states that polymyxin B dosage "should be reduced in the presence of renal impairment" 2, but this recommendation is contradicted by more recent pharmacokinetic evidence and clinical guidelines.

Evidence Supporting No Dose Adjustment

Multiple high-quality studies demonstrate:

• Guideline consensus (2015): The Intensive Care Medicine task force explicitly states that polymyxin B dosages "should be calculated based on body weight, while the plasma concentration is not influenced by renal function" and that "for patients on continuous renal replacement therapy, dose adjustment is not necessary" 1

• Pharmacokinetic studies: Research consistently shows no significant difference in polymyxin B exposure (AUC) between patients with normal renal function versus renal insufficiency. One study found mean AUC of 63.5 ± 16.6 mg·h/L in normal renal function versus 56.0 ± 17.5 mg·h/L in renal insufficiency (p=0.42) 3

• Clinical outcomes: Multiple studies found no difference in acute kidney injury (AKI) rates between adjusted versus unadjusted doses based on renal function (47.5% vs 37.14%, p=0.304 4; 20.0% vs 18.2%, p=0.882 5)

Special Populations

Patients on Continuous Renal Replacement Therapy (CRRT):

• Use the same dose as patients with normal renal function 1
• No dose adjustment necessary 1

Patients with severe renal impairment:

• Recent population pharmacokinetic studies suggest that while creatinine clearance does affect polymyxin B clearance, the clinical relevance of dose adjustment remains uncertain 6, 7, 8
• Some newer evidence suggests dose reduction may be considered in severe renal insufficiency, but this conflicts with established guidelines 7, 8

Critical Safety Considerations

Monitor renal function closely:

• Polymyxin B carries nephrotoxicity risk (14.7-25% incidence of AKI) 6, 9
• The incidence of renal failure appears lower with polymyxin B than with colistin 1
• Perform baseline and regular monitoring of serum creatinine, BUN, and urine output 2

Avoid concurrent nephrotoxic drugs:

• Do not combine with aminoglycosides, vancomycin, or other nephrotoxic agents when possible 10, 2

Therapeutic drug monitoring (TDM):

• Strongly recommended when available to optimize efficacy and minimize toxicity 10, 6, 8
• Target steady-state concentrations based on MIC of the organism

Common Pitfall to Avoid

Do not confuse polymyxin B with colistin. Colistin (polymyxin E) DOES require dose adjustment for renal function, with maintenance doses adjusted according to creatinine clearance 1. The two drugs have fundamentally different pharmacokinetics because colistin is given as an inactive prodrug that requires renal conversion.